$400 Million Biological Safety Cabinet (Class I, Class II, Class III) Markets - Global Forecast to 2027: Increased Risk of Pandemics and Communicable Diseases to Drive Market - ResearchAndMarkets.com
02 Dec 2022
DUBLIN--(BUSINESS WIRE)--The "Biological Safety Cabinet Market by Type (Class I, Class II (Type A, Type B), Class III), End User (Pharmaceutical & Biopharmaceutical Companies, Diagnostic & Testing Laboratories, Academic Research Institutes), and Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
'Biological Safety Cabinet Market by Type (Class I, Class II (Type A, Type B), Class III), End User (Pharmaceutical & Biopharmaceutical Companies, Diagnostic & Testing Laboratories, Academic Research Institutes), and Region - Global Forecast to 2027'
The global biological safety cabinet market is projected to reach USD 0.4 billion by 2027 from USD 0.2 billion in 2022, at a CAGR of 8.2%.
Market growth is driven by factors such as increased production of biosimilar products and increased research for vaccines. On the other hand, the challenges associated with biological safety cabinet is alternative containment cabinets is the major factors hampering the growth of this market.
The class II segment accounted for the highest growth rate in the biological safety cabinet market, by type, during the forecast period
The biological safety cabinet market is segmented into class I, class II and class III. In 2021, class II segment accounted for the highest growth rate in the biological safety cabinet market. The growing pharmaceutical and biopharmaceutical industry and growing concerns over cell culture contamination are a major factor contributing to the growth of this segment.
The pharmaceutical and biopharmaceutical companies segment accounted for the highest growth rate in the biological safety cabinet market, by end-user, during the forecast period
The biological safety cabinet market is segmented into pharmaceutical and biopharmaceutical companies, diagnostic and testing laboratories and academic research institutes based on the type of waste.
In 2021, the pharmaceutical and biopharmaceutical companies segment accounted for the highest growth rate in the biological safety cabinet market. Emerging markets offer lucrative growth opportunities are major factors contributing to the growth of this segment.
Asia Pacific: The fastest-growing region in biological safety cabinet market
The Asia Pacific region is projected to register the highest CAGR during the forecast period. Increasing number of conferences focused on creating awareness of biosafety is driving the growth of the biological safety cabinet market in this region.
Competitive landscape
The key players in this market are Thermo Fisher Scientific (US), Kewaunee Scientific (US), Labconco (US), Esco Micro (Singapore), The Baker Company (US), NuAire (US), Germfree Laboratories (US), Cruma (Spain), Air Science (US), Berner International (US), Azbil Telstar (Spain), LaboGene (Denmark), Biolab Scientific (Canada), LAMSYSTEMS (Germany), and Faster S.r.l. (Italy).
Premium Insights
Increased Risk of Pandemics and Communicable Diseases to Drive Market
Class II Segment Will Continue to Dominate Market in 2027
Pharmaceutical and Biopharmaceutical Companies - Largest End-users of Biological Safety Cabinets
Asia-Pacific Region to Register Highest Growth in Forecast Period
Market Dynamics
Favorable Regulations
Increased Risk of Pandemics and Communicable Diseases
Increasing Number of R&D Activities in Pharmaceutical and Biopharmaceutical Companies
Rapid Growth in Biologics
Growing Concerns Over Cell Culture Contamination
Restraints
Alternative Containment Cabinets
High Cost of Biological Safety Cabinets
Opportunities
Emerging Markets Offer Lucrative Growth Opportunities
Case Studies
Case Study: Laboratory Biological Safety Cabinet (Bsc) Explosion
Company Profiles
Thermo Fisher Scientific
Nuaire
Cruma
Lamsystems GmbH
Other Players
Mrc Laboratory Equipment
Nanbei Instrument Limited
Labmate
Topair Systems, Inc.
Albian Group
Thomas Scientific
Zhejiang Fuxia Medical Technology Co. Ltd.
Stericox
For more information about this report visit https://www.researchandmarkets.com/r/wmzy6z
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.